Actin filament-associated protein 1-antisense RNA1 (AFAP1-AS1), a cancer-related long non-coding RNA, has been found to be upregulated in multiple types of cancers. AFAP1-AS1 is important for the initiation, progression and poor prognosis of many cancers, including nasopharyngeal carcinoma (NPC). However, the mechanism underlying the regulation of AFAP1-AS1 expression is not well-understood. In our study, the potential promoter region of AFAP1-AS1 was predicted by comprehensive bioinformatics analysis. Moreover, promoter deletion analysis identified the sequence between positions -359 and -28 bp as the minimal promoter region of AFAP1-AS1. The ChIP assay results indicate that the AFAP1-AS1 promoter is responsive to the transcription factor c-Myc, which can promote high AFAP1-AS1 expression. This study is the first to clone and characterize the AFAP1-AS1 promoter region. Our findings will help to better understand the underlying mechanism of high AFAP1-AS1 expression in tumorigenesis and to develop new strategies for therapeutic high expression of AFAP1-AS1 in NPC.
Introduction
Nasopharyngeal carcinoma (NPC) is one of the most common head and neck cancers arising from the nasopharynx epithelium [1] [2] [3] . NPC has a distinctive ethnic and geographic distribution and represents a serious health problem in Southeast Asia and southern China, especially in Guangdong Province [4, 5] . The etiology of NPC is multifactorial, including Epstein-Barr virus infection, heredity and environmental factors [6] [7] [8] [9] . NPC tumorigenesis often involves inactivation of several tumor suppressor genes and abnormal activation of several oncogenes [10] [11] [12] [13] , among which an increasing number of long non-coding RNAs (lncRNAs) have been identified in recent years [14] [15] [16] [17] . LncRNAs are more than 200 nucleotides in length and have no open reading frame. Dysregulation of lncRNAs has been shown to be involved in the development and progression of NPC [18] [19] [20] .
Among many cancer-related lncRNAs, the recently identified actin filament-associated protein 1-antisense RNA1 (AFAP1-AS1) has been the focus of great interest [21, 22] . AFAP1-AS1 is derived from the
Ivyspring International Publisher
antisense DNA strand of the AFAP1 coding gene locus, and dysregulated expression of AFAP1-AS1 has been found in many types of cancers, including NPC [23, 24] . In our previous study, cDNA microarray analysis of lncRNA expression showed that AFAP1-AS1 is significantly upregulated in NPC. Consistent with this observation, AFAP1-AS1 expression is also upregulated in NPC tissues [25] . In addition, AFAP1-AS1 knockdown significantly suppresses the metastasis and invasion of NPC [26] . Moreover, high AFAP1-AS1 expression is associated with a poor prognosis of NPC patients [27] . However, to our knowledge, a potential mechanism of high AFAP1-AS1 expression in NPC has not been reported.
To understand the mechanism underlying AFAP1-AS1 regulation, we investigated whether AFAP1-AS1 expression was regulated at the level of transcription initiation. Through a comprehensive bioinformatics prediction, the potential promoter region of AFAP1-AS1 was identified and cloned. Furthermore, the transcription factor c-Myc was predicted to be associated with the AFAP1-AS1 promoter and to promote AFAP1-AS1 expression. In addition, deletion analysis identified a 332-bp fragment comprising the minimal promoter region of AFAP1-AS1. This study provides the basis for unraveling the potential mechanism of abnormal AFAP1-AS1 expression in NPC tumorigenesis.
Materials and methods

Cell lines, cell culture and transfection
The NPC cell line HNE2 was maintained in our laboratory and grown in RPMI-1640 medium (Life Technologies, Grand Island, NY) supplemented with 10% fetal bovine serum (FBS; Life Technologies) and 1% penicillin-streptomycin solution (Life Technologies). Cells were incubated at 37°C in a humidified atmosphere with 5% CO 2 . Transfection was performed using Lipofectamine 3000 reagent (Life Technologies) according to the manufacturer's protocol.
Cloning of the human AFAP1-AS1 promoter reporter constructs
The potential promoter region -1521/+220 of AFAP1-AS1 and a series of 5'-and 3'-deletion fragments (-1050/+220, -1050/-28, -1050/-80, -1050/-359, -881/-28, -496/-28 and -359/-28) were amplified by PCR using the primers listed in Table 1 . All of the primers included 15-bp sequences homologous to the pGL3-enhancer luciferase reporter vector (Promega, Madison, WI, USA). Construct naming is based on the positions of the promoter fragments. The promoter fragments were then inserted into the pGL3-enhancer vector between the NheI and HindIII sites with ClonExpress ® II One Step Cloning Kit (Vazyme, Nanjing, China). The recombinants were then transformed into Escherichia coli JM109 and confirmed by DNA sequencing.
Luciferase reporter assay
Promoter activities were detected using the dual-luciferase reporter assay system (Promega) according to the manufacturer's instructions. Briefly, HNE2 cells were transfected with 0.1 μg of Renilla luciferase expression plasmid pRL-TK (internal control for normalizing transfection efficiency; Promega) and 0.4 μg of various AFAP1-AS1 promoter constructs, pGL3-control plasmid (positive control; Promega), or pGL3-enhancer plasmid (negative control). The firefly luciferase readings were normalized by the Renilla luciferase readings to calculate the relative fold-change. Every transfection was independently repeated three times, and the mean ± standard deviation (SD) was used to express the relative fold-change. 
RNA extraction and quantitative real-time PCR (qPCR)
Total RNAs were extracted using the TRIzol Extraction Kit (Invitrogen, Carlsbad, CA), according to the manufacturer's instructions. The cDNA was prepared from total RNA using 5X All-In-One RT Master Mix (Applied Biologic Materials (abm), Richmond, Canada), after which real-time qPCR reactions were performed using the Bio-Rad CFX Connect Real-Time system (Bio-Rad, Hercules, CA) with SYBR Green (abm). The expression of each target gene was quantified by the comparative CT method using GAPDH as an endogenous control. The following primers were synthesized by Life Technologies and used to amplify AFAP1-AS1, c-Myc and GAPDH: AFAP1-AS1 forward primer (5'-AAT GGT GGT AGG AGG GAG GA-3'), reverse primer (5'-CAC ACA GGG GAA TGA AGA GG-3'); c-Myc forward primer (5'-CCT ACC CTC TCA ACG ACA GC-3'), reverse primer (5'-TTC CTC CTC AGA GTC GCT GC-3'); and GAPDH forward primer (5'-CAA CGG ATT TGG TCG TAT TGG-3'), reverse primer (5'-TGA CGG TGC CAT GGA ATT T-3'). All reactions were run in triplicate and repeated in three independent experiments.
Chromatin immunoprecipitation (ChIP) assay
ChIP assays were performed in HNE2 cells using a kit from Millipore (Billerica, MA, USA) according to manufacturer's protocol. Cells were fixed in 1% formaldehyde for 10 min at room temperature to crosslink proteins to DNA, after which fixed cells were washed, lysed in cell lysis buffer supplemented with a protease-inhibitor cocktail, and sonicated to shear crosslinked DNA. Then, ~10% of sonicate was saved as an input sample. The crosslinked protein/DNA complexes were immunoprecipitated using the c-Myc antibody, the immunocomplexes were eluted, and the protein/DNA crosslinking was then reversed to release the DNA. The enrichment of purified DNA fragments was determined by real-time PCR using the following two primer sets for AFAP1-AS1: forward primer set 1, TGC ATG ATG ACA CAG AGG GT (start: -1305), reverse primer set 1, GAG GAT ATA GAG GAC TTG GGC T (start: -1166); forward primer set 2, CTC CCG CCA TGA TTC TGA G (start site: +30), and reverse primer set 2, CTT GGC CCA ATT CCT CCT G (start site: +145). Nonspecific antibody (IgG) served as a negative control.
Bioinformatics analysis
The gene sequence of human AFAP1-AS1 was obtained from NCBI. The potential promoter region of the AFAP1-AS1 was predicted using the online 
Statistical analysis
Statistical analyses were performed using GraphPad Prism 5 (GraphPad, La Jolla, CA). Student's t-test was used to evaluate significant differences between two groups of data. All data are represented as the means ± standard deviation. P < 0.05 was considered statistically significant.
Results
Bioinformatics analysis of the AFAP1-AS1 promoter region
To better understand the mechanism involved in the high AFAP1-AS1 expression in NPC, we used various bioinformatics tools to analyze the potential promoter region of AFAP1-AS1. The AFAP1-AS1 sequence was obtained from the National Center for Biotechnology Information (NCBI). The 2000-bp region between positions -1600 bp and +400 bp (the transcription start site was designated as +1) was identified and analyzed. The promoter sequence was analyzed by BDGP, promoter 2.0, and Neural Network Promoter Prediction. A CpG island between positions -1145 and -477 was detected using CpG Islands, CpGProD, and CpG Island Searcher programs.
Based on this comprehensive bioinformatics analysis, we chose the region between positions -1521 and +220 for further study (Figure 1) .
Construction of the reporter vector for the AFAP1-AS1 promoter
To analyze the transcriptional regulation of AFAP1-AS1, we used human peripheral blood-originated genomic DNA as the template to isolate the AFAP1-AS1 promoter region. A band with an expected size of approximately 1741 bp was successfully amplified and verified by electrophoresis in 1% agarose gel (Figure 2A) . The fragment was then cloned into the pGL3-enhancer vector and sequenced ( Figure 2B ). HNE2 cells were transiently transfected with the AFAP1-AS1 promoter construct (pGL3-1521/+220), and the luciferase activity was then measured. As shown in Figure 2C , the pGL3-1521/+220 construct had a higher luciferase activity than the negative control (relative luciferase 
Identification of potential transcription factor binding sites in the AFAP1-AS1 promoter region in NPC cells
We used the UCSC website to predict potential transcription factor binding sites in the region between positions -1521 and +220 of AFAP1-AS1. Several putative binding sites for transcription factors were identified in this region, including c-Myc, ZBTB33, and CHD2. Considering that c-Myc is a very common transcriptional regulator [28, 29] , we selected this transcription factor for subsequent validation ( Figure 3A) .
To verify whether c-Myc has a regulatory function in AFAP1-AS1 expression, a c-Myc overexpression vector was transiently transfected to express c-Myc in HNE2 cells ( Figure 3B ). As shown in Figure 3C , c-Myc overexpression can increase AFAP1-AS1 expression (P=0.027). To determine whether c-Myc binds specifically to the AFAP1-AS1 promoter, we performed chromatin immunoprecipitation (ChIP) assays in HNE2 cells. Two sets of primers for the AFAP1-AS1 promoter in close proximity to two predicted binding sites in the -1521/+220 region were used for real-time PCR. ChIP with an antibody against c-Myc resulted in a significant enrichment of the AFAP1-AS1 promoter region using both primer sets, compared to the control IgG (P=0.010 and 0.009, Figure 3D ). Thus, these data indicate that c-Myc is the main transcription factor that promotes high AFAP1-AS1 expression in NPC cells.
Deletion analysis of the AFAP1-AS1 promoter in NPC cells
To identify the core promoter region of AFAP1-AS1, a series of progressive deletion fragments were generated and subcloned into the pGL3-enhancer vector. These constructs (plasmids pGL3-1521/+220, pGL3-1050/+220, pGL3-1050/-28, pGL3-1050/-80, pGL3-1050/-359, pGL3 -881/-28, pGL3-496/-28 and pGL3-359/-28, depicted in Figure  4A ) were transiently transfected into HNE2 cells, and the luciferase activities driven by the AFAP1-AS1 promoter constructs were measured.
As shown in Figure 4B , we standardized the negative control (pGL3-enhancer) to 1, and the luciferase activity from constructs pGL3-1050/-28 (60.560 ± 3.898), pGL3-881/-28 (63.520 ± 2.889) and pGL3-496/-28 (64.220 ± 1.774) exhibited similar levels in HNE2 cells. These levels were higher than those from constructs pGL3-1521/+220 (54.410 ± 4.313) and pGL3-1050/+220 (51.670 ± 3.945). The reporters driven by the shorter 332-bp fragment (PGL3-359/-28) showed the highest luciferase activity (65.740 ± 4.514, P<0.001, in comparison with a negative control). However, when the region between -80 and -28 was deleted, there was a remarkable reduction in luciferase activity (26.190 ± 1.936). Moreover, the pGL3-1050/-359 construct showed nearly no luciferase expression (0.741 ± 0.074, P=0.683, in comparison with a negative control), and it displayed a significantly lower luciferase activity compared to that of pGL3-1050/-28. In conclusion, the above data show that the region between positions -359 and -28 contains the core promoter that activates AFAP1-AS1 transcription and is necessary and required for basal transcriptional activity of AFAP1-AS1.
Discussion
Long non-coding RNAs (lncRNAs) are often defined as transcribed non-coding RNAs that are longer than 200 nucleotides and have no significant protein-coding potential [30] [31] [32] . In the past, lncRNAs were mistaken for transcriptional "noise". However, with the advancement of high-throughput technologies, an increasing number of studies have focused on important roles of lncRNAs in a wide range of physiological and pathological processes, especially in cancers [33] [34] [35] . LncRNAs may act as tumor suppressors or oncogenes by regulating target gene expression at the transcriptional, posttranscriptional, and epigenetic levels. LncRNAs can affect the initiation, progression, and prognosis of various cancers, including NPC [36] [37] [38] [39] . A growing number of lncRNAs have been reported to be closely associated with proliferation, apoptosis, metastasis, and radiation response of NPC cells, including MALAT-1 [40] , LINC01420 [41] , LOC553103 [42] , LOC401317 [43] , and AFAP1-AS1 [27] .
Long non-coding RNA AFAP1-AS1 is located in the 4p16.1 region of human chromosome 4, derives from the antisense DNA strand of the AFAP1 gene, and can regulate the expression of AFAP1 [27] . AFAP1-AS1 was initially discovered in Barrett's esophagus and esophageal adenocarcinoma in 2013 [44] . Our in-depth study of AFAP1-AS1 functions in NPC and lung cancer progression showed that high AFAP1-AS1 expression might promote cell metastasis and invasion via regulation of the small GTPase Rho/Rac signaling pathway and actin filament integrity [23, 27] . In recent years, numerous studies have demonstrated that high AFAP1-AS1 levels are found in a variety of cancers, including esophageal squamous cell carcinoma [45] , non-small cell lung cancer [46] , pancreatic ductal adenocarcinoma [47] , hepatocellular carcinoma [48] , colorectal [49] , cholangiocarcinoma [50] , gastric [51] , and gallbladder cancer [52] . In addition, the dysregulated expression of AFAP1-AS1 is often associated with cell proliferation, cell cycle progression, angiogenesis, invasion, metastasis, radioresistance and poor prognosis of cancers [53, 54] .
The mechanisms behind the abnormal AFAP1-AS1 expression in cancers are not well-understood. A single study on AFAP1-AS1 showed that it was hypomethylated and overexpressed in Barrett's esophagus and esophageal adenocarcinoma [44] . Considering that transcriptional regulation is one of the most important components of gene expression regulation [55] , we investigated the mechanisms regulating AFAP1-AS1 expression at the level of transcription. Our comprehensive analysis of the CpG island and promoter prediction showed that the -1521/+220 region of AFAP1-AS1 contains the potential promoter, and a luciferase reporter driven by the promoter of AFAP1-AS1 showed high expression in HNE2 cells.
Analysis of the -1521/+220 promoter region of AFAP1-AS1 by bioinformatics methods showed putative binding sites for transcription factors, such as c-Myc, ZBTB33, and CDH2. It is noteworthy that c-Myc has two binding sites in this region of AFAP1-AS1. The c-Myc proto-oncogene is a vital member of the Myc/Mad/Max transcription factor network, which regulates nearly 15% of genes in the human genome [56] [57] [58] , and thereby participates in the regulation of various pathological processes in cancers [59, 60] . Thus, c-Myc was selected as a possible candidate transcription factor for regulation of AFAP1-AS1 expression. Our research demonstrated that the AFAP1-AS1 promoter is responsive to c-Myc and that c-Myc overexpression can increase the expression of AFAP1-AS1, indicating that c-Myc may be the main transcription factor that promotes high AFAP1-AS1 expression in NPC.
To identify the necessary and required region for the basal transcriptional activity of AFAP1-AS1, a series of deletion constructs based on pGL3-1521/+220 were generated and transfected in HNE2 cells. We found that the reporters driven by the shorter 332-bp fragment (PGL3-359/-28) showed the highest luciferase activity, and the deletion between positions -80 and -28 caused a significant decrease in promoter activity. Moreover, the luciferase expression was almost undetectable with the pGL3-1050/-359 construct. Thus, a region from -359 to -28 was identified as the minimal sequence that contains the core promoter and controls promoter activity. In addition to c-Myc, we also predicted several other putative transcription factor binding sites in the promoter region of AFAP1-AS1. Among these transcription factors, CDH2 [61] , ZBTB33 [62] , POLR2A [63] , KDM5B [64] , MAX [28] , and ETS1 [65] have been proven to be upregulated in different types of cancers and are closely related to tumorigenesis and tumor progression [66] [67] [68] [69] . Remarkably, the ETS1 and Myc promoter signals are well-correlated and share many properties; for example, Myc and ETS1 can collaborate to increase expression of some oncogenic genes [65] . In addition, Myc and KDM5B can form a nuclear complex that promotes expression of several genes associated with tumorigenesis [70] . Furthermore, the Myc/MAX network comprises a group of transcription factors whose distinct interactions result in gene-specific transcriptional activation [71] . Therefore, Myc and other predicted transcription factors may exert a synergistic effect on the regulation of high AFAP1-AS1 expression.
In conclusion, to our knowledge, this study is the first to clone and characterize the promoter region of AFAP1-AS1. We found that the transcriptional factor c-Myc plays an important role in enhancing AFAP1-AS1 expression. Our findings provide new insights into unraveling the underlying mechanism of high AFAP1-AS1 expression in tumorigenesis.
